Search results
Showing 31 to 38 of 38 results for tocilizumab
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)
Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with severe active ankylosing spondylitis or severe non-radiographic axial spondyloarthritis who have tried non-steroidal anti-inflammatory drugs (NSAIDs), but they have not worked.
The NICE real-world evidence framework aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Show all sections
- Overview
- Introduction to real-world evidence in NICE decision making
- Conduct of quantitative real-world evidence studies
- Assessing data suitability
- Methods for real-world studies of comparative effects
- Appendix 1 - Data Suitability Assessment Tool (DataSAT)
- Appendix 2 - Reporting on methods used to minimise risk of bias
- Appendix 3 - Reporting information for selected analytical methods
Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.
Dr Ravinder Claire outlines recent progress towards greater use of real-world evidence in regulatory decision-making. He also considers the implications and opportunities for NICE and our stakeholders.
Three treatments for COVID-19 recommended in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.